الإحصائيات الأساسية
| CIK | 722104 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Savient Pharmaceuticals Inc
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| May 30, 2014 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : x NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT FOR THE PERIOD OF MAY 1, 2014 THROUGH MAY 31, 2014 PLEASE TAKE NOTICE that the debtors and debtors-in-possession in the above- |
|
| May 30, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 30, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 20, 2014 |
EX-99.2 Exhibit 99.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x In re: SAVIENT PHARMACEUTICALS, INC., et al., Debtors.1 : : : : : : : : x Chapter 11 Case No. 13-12680 (MFW) Jointly Administered NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT FOR THE PERIOD OF APRIL 1, 2014 THROUGH APRIL 30, 2014 PLEASE TAKE NOTICE that the debtors and debtors-in-possession in the ab |
|
| May 20, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 19, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Comm |
|
| May 20, 2014 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : Chapter 11 In re: : : Case No. 13-12680 (MFW) SAVIENT PHARMACEUTICALS, INC., : et al., : Jointly Administered : Debtors.1 : Related to Docket No. 490, 625, 640 : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x FINDINGS |
|
| April 17, 2014 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING R |
|
| April 17, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 17, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Co |
|
| March 21, 2014 |
EX-99.1 2 d697032dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x NOTICE OF FILING OF |
|
| March 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d697032d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of In |
|
| March 18, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Commission |
|
| March 18, 2014 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE EX-99.2 Exhibit 99.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x |
|
| March 18, 2014 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x |
|
| February 21, 2014 |
Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - : x NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT FO |
|
| February 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 11, 2014 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x In re: SAVIENT PHARMACEUTICALS, INC., et al., Debtors.1 : : : : : : : : Chapter 11 Case No. 13-12680 (MFW) Jointly Administered - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x PLAN OF LIQUIDATION PURSUANT |
|
| February 11, 2014 |
SVNTQ / Savient Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment savi13a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 80517Q100 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SAVIENT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2013 (Date of E |
|
| February 11, 2014 |
THIS DISCLOSURE STATEMENT HAS NOT YET BEEN APPROVED BY THE COURT EX-99.2 Exhibit 99.2 THIS DISCLOSURE STATEMENT HAS NOT YET BEEN APPROVED BY THE COURT This proposed Disclosure Statement is not a solicitation of acceptance or rejection of the Plan of Liquidation Pursuant To Chapter 11 of the Bankruptcy Code Proposed by the Debtors. Acceptances or rejections may not be solicited until the Bankruptcy Court has approved this Disclosure Statement under section 1125 |
|
| February 11, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) |
|
| February 11, 2014 |
SVNTQ / Savient Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment savientpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Savient Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 80517Q100 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check th |
|
| January 22, 2014 |
Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : x NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT FOR THE PERIOD OF DECEMBER 1, 2013 THROUGH DECEMBER 31, 2013 PLEASE TAKE NOTICE that the debtors and debtors-in-possession in the abov |
|
| January 22, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 21, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) ( |
|
| January 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 8, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 10, 2014 |
AMENDMENT TO THE SAVIENT PHARMACEUTICALS, INC. Effective January 8, 2014 EX-3.1 Exhibit 3.1 AMENDMENT TO THE BY-LAWS OF SAVIENT PHARMACEUTICALS, INC. Effective January 8, 2014 The By-Laws (the “By-Laws”) of Savient Pharmaceuticals, Inc., a Delaware corporation, as amended through August 5, 2012, are hereby amended as follows, effective January 8, 2014: 1. Article III, Section 1 of the By-Laws is hereby amended by replacing the first sentence of Section 1 with the follo |
|
| January 7, 2014 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : Chapter 11 In re: : : Case No. 13-12680 (MFW) SAVIENT PHARMACEUTICALS, INC., : et al., : Jointly Administered : Debtors.1 : Related to Docket Nos. 16, 43, 250, 295 : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x CERT |
|
| January 7, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2014 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 31, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) |
|
| December 31, 2013 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : Chapter 11 In re: : : Case No. 13-12680 (MFW) SAVIENT PHARMACEUTICALS, INC., : et al., : Jointly Administered : Debtors.1 : Related to Docket Nos. 16, 43, 250 : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x NOTICE OF |
|
| December 20, 2013 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : x NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT FOR THE PERIOD OF NOVEMBER 1, 2013 THROUGH NOVEMBER 30, 2013 PLEASE TAKE NOTICE that the debtors and debtors in possession in |
|
| December 20, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) |
|
| December 16, 2013 |
EX-2.1 2 d643217dex21.htm EX-2.1 Exhibit 2.1 EXECUTION VERSION ACQUISITION AGREEMENT among SAVIENT PHARMACEUTICALS, INC. AND SAVIENT PHARMA HOLDINGS, INC., as Sellers, and CREALTA PHARMACEUTICALS LLC as Purchaser Dated as of December 10, 2013 TABLE OF CONTENTS ARTICLE I THE ACQUISITION 1 Section 1.1 Acquired Assets 1 Section 1.2 Excluded Assets 3 Section 1.3 Assumed Liabilities 4 Section 1.4 Exclu |
|
| December 16, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d643217d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 10, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of |
|
| December 16, 2013 |
EX-99.1 3 d643217dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Debtors.1 : Jointly Administered : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - x Related Docket No. 1 |
|
| December 5, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 5, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 5, 2013 |
EX-99.1 2 d638268dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : x NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT FOR THE PERIOD OF OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013 PLEASE TAKE NOTICE that the debtors an |
|
| November 21, 2013 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 21, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 14, 2013 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 12, 2013 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G CUSIP No. 80517Q100 EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G (and any amendments or supplements thereto) required under section 13(d) of the Securities Exchange Act of 1934, as amended, in connection with purchase |
|
| November 12, 2013 |
SVNTQ / Savient Pharmaceuticals Inc / Palo Alto Investors LP - AMENDMENT NO. 14 Passive Investment SC 13G/A 1 te13422513ga.htm AMENDMENT NO. 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14) Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80517Q100 (CUSIP Number) October 15, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 6, 2013 |
EX-99.1 2 d623697dex991.htm EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : Related Docket No. 94 x NOTICE OF FILING OF SUPPLEMENT TO INITIAL MONTHLY OPERATING REPORT PLEASE TAKE NOTICE that on October 29, 2013, the debtors and de |
|
| November 6, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d623697d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdictio |
|
| October 30, 2013 |
EX-99.1 Exhibit 99.1 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE x : In re: : Chapter 11 : SAVIENT PHARMACEUTICALS, INC., : Case No. 13-12680 (MFW) et al., : : Jointly Administered Debtors.1 : : x NOTICE OF FILING OF INITIAL MONTHLY OPERATING REPORT PLEASE TAKE NOTICE that the debtors and debtors in possession in the above-captioned jointly administered bankruptcy cases (col |
|
| October 30, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) ( |
|
| October 15, 2013 |
EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE SAVIENT PHARMACEUTICALS COMMENCES VOLUNTARY CHAPTER 11 PROCEEDING; SEEKS TO CONDUCT AUCTION AND SALE UNDER SECTION 363 Enters into “Stalking Horse” Sale Agreement with US WorldMeds, LLC KRYSTEXXA® Remains Commercially Available in United States BRIDGEWATER, N.J. – October 14, 2013 – Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) (“Savient”) announced today |
|
| October 15, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) ( |
|
| October 15, 2013 |
FORM OF INCENTIVE BONUS AGREEMENT EX-10.1 Exhibit 10.1 FORM OF INCENTIVE BONUS AGREEMENT This Incentive Bonus Agreement (this “Agreement”) between Savient Pharmaceuticals, Inc. (the “Company”), and [ ] (“Employee”) is made and entered into effective as of the date the Employee executes this Agreement as set forth below (the “Effective Date”). RECITALS A. Employee occupies a key position with the Company. In order to ensure the con |
|
| October 15, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2013 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) |
|
| October 15, 2013 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION ACQUISITION AGREEMENT among SAVIENT PHARMACEUTICALS, INC. AND SAVIENT PHARMA HOLDINGS, INC., as Sellers, and US WORLDMEDS, LLC AND SLOAN HOLDINGS C.V. as Purchaser Parties Dated as of October 14, 2013 TABLE OF CONTENTS ARTICLE I THE ACQUISITION 1 Section 1.1 Acquired Assets 1 Section 1.2 Excluded Assets 3 Section 1.3 Assumed Liabilities 4 Section 1.4 Excluded L |
|
| August 14, 2013 |
Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results EX-99.1 Exhibit 99.1 Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results BRIDGEWATER, N.J., Aug. 14, 2013 /PRNewswire/ — Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six-month periods ended June 30, 2013. Net sales for KRYSTEXXA® were $6.1 million for the second quarter of 2013, a 38% increase over the first quarter of 2013. For |
|
| August 14, 2013 |
Fastenal FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 14, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2013 (August 14, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of |
|
| July 25, 2013 |
CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE EX-10.1 Exhibit 10.1 EXECUTION COPY CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE THIS CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE (“Separation Agreement”) is made and entered into by and between Louis Ferrari (“you”) and Savient Pharmaceuticals, Inc. (“Savient” or the “Company”) (Savient and you, together, the “Parties”). RECITALS WHEREAS, Savient has employed you since February |
|
| July 25, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2013 (July 23, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Inc |
|
| June 20, 2013 |
Savient Pharmaceuticals Announces Formation of Office of the President EX-99.1 Exhibit 99.1 CONTACT: Savient Pharmaceuticals, Inc. Burns McClellan John P. Hamill Caitlyn E. Murphy Co-President and Chief Financial Officer [email protected] [email protected] (212) 213-0006 (732) 418-9300 Savient Pharmaceuticals Announces Formation of Office of the President Bridgewater, N.J. - (June 20, 2013) – Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that i |
|
| June 20, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2013 (June 20, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Inc |
|
| June 14, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2013 (June 13, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Inc |
|
| June 13, 2013 |
Regulation FD Disclosure - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2013 (June 13, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Inc |
|
| June 4, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 15, 2013 |
Fastenal FORM 10-Q (Quarterly Report) Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 15, 2013 |
Savient Pharmaceuticals Reports First Quarter 2013 Financial Results EX-99.1 Exhibit 99.1 Savient Pharmaceuticals Reports First Quarter 2013 Financial Results BRIDGEWATER, N.J., May 15, 2013 /PRNewswire/ — Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2013. Net sales of KRYSTEXXA® (pegloticase) were $4.4 million for the first quarter of 2013, a 6% decrease from the fourth quarter of 2012 and a 43% |
|
| May 15, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2013 (May 15, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incor |
|
| April 30, 2013 |
Notice and Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 11, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2013 (April 8, 2013) Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) DE 0-15313 13-3033811 (State or other jurisdiction of inco |
|
| April 1, 2013 |
POS AM As filed with the Securities and Exchange Commission on April 1, 2013 Registration No. |
|
| March 21, 2013 |
EX-99.1 Exhibit 99.1 Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results BRIDGEWATER, N.J., March 19, 2013 /PRNewswire/ — Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months and full year ended December 31, 2012. Savient ended the quarter with approximately $96.3 million in cash and short-term investments, a decrease of |
|
| March 21, 2013 |
EX-99.2 3 d504317dex992.htm EX-99.2 Exhibit 99.2 Savient Pharmaceuticals, Inc. SVNT Q4 2012 Earnings Call Mar. 19, 2013 Companyp Tickerp Event Typep Datep PARTICIPANTS Corporate Participants Philip K. Yachmetz – Senior Vice President and General Counsel, Savient Pharmaceuticals, Inc. Louis Ferrari – President, Chief Executive Officer & Director, Savient Pharmaceuticals, Inc. John P. Hamill – Chief |
|
| March 21, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2013 (March 19, 2013) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of I |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2013 |
SVNTQ / Savient Pharmaceuticals Inc / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment SC 13G/A 1 a13-44363sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* SAVIENT PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 80517Q100 (CUSIP Number) DECEMBER 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2013 |
SVNTQ / Savient Pharmaceuticals Inc / Palo Alto Investors LP Passive Investment SC 13G/A 1 savient13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13) Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 12, 2013 |
SVNTQ / Savient Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 80517Q100 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SAVIENT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| February 12, 2013 |
SVNTQ / Savient Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment savientpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Savient Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 80517Q100 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check th |
|
| February 5, 2013 |
SVNTQ / Savient Pharmaceuticals Inc / SAMANA CAPITAL, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 8, 2013 |
Press Release Exhibit 99.1 Contact: Savient Pharmaceuticals, Inc. John P. Hamill Senior Vice President and Chief Financial Officer [email protected] (732) 418-9300 Burns McClellan Caitlyn Murphy [email protected] (212) 213-0006 Savient Pharmaceuticals Announces the Election of Genzyme CEO Dr. David Meeker to Its Board of Directors BRIDGEWATER, N.J., (January 8, 2013) – Savient Pharmaceutic |
|
| January 8, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 01/06/2013 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of |
|
| December 31, 2012 |
Form 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 12/28/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of i |
|
| December 10, 2012 |
Savient Announces the Election of Robert G. Savage to its Board of Directors Press Release Exhibit 99.1 Contact: Savient Pharmaceuticals, Inc. Burns McClellan John P. Hamill Caitlyn Murphy Senior Vice President and Chief Financial Officer [email protected] [email protected] (212) 213-0006 (732) 418-9300 Savient Announces the Election of Robert G. Savage to its Board of Directors BRIDGEWATER, N.J., (December 5, 2012) – Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) to |
|
| December 10, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 12/05/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of |
|
| December 10, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K/A 1 d450990d8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 11/08/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3 |
|
| December 10, 2012 |
Transcript Exhibit 99.2 1 THOMSON REUTERS STREETEVENTS |www.streetevents.com | Contact Us © 2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. ‘Thomson Reuters’ and the Thomson Reuters logo are registered trademarks of Thomson Reuters and it |
|
| December 10, 2012 |
Press Release Exhibit 99.1 November 8, 2012 Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results BRIDGEWATER, N.J., Nov. 8, 2012 /PRNewswire/ — Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and nine months ended September 30, 2012, which reflects the Company’s continuing commercialization of KRYSTEXXA® (pegloticase) in the U.S. Savient |
|
| November 14, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 11/08/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| October 9, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on October 9, 2012 Registration No. |
|
| October 9, 2012 |
STOCK OPTION AGREEMENT (Non-Qualified Stock Option to Employee) Non-Qualified Stock Option Agreement between the Registrant and John P Hamill Exhibit 99. |
|
| October 9, 2012 |
STOCK OPTION AGREEMENT (Non-Qualified Stock Option to Employee) Exhibit 99.1 STOCK OPTION AGREEMENT (Non-Qualified Stock Option to Employee) NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) made as of September 24, 2012, between SAVIENT PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and John P. Hamill, an employee of the Company or of a subsidiary of the Company (the “Optionee”). 1. Grant of Option. The Company hereby grants to the Optio |
|
| September 27, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2012 Savient Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation |
|
| September 27, 2012 |
Employment Agreement Execution Copy Exhibit 10.1 EMPLOYMENT AGREEMENT This Agreement is made, entered into, and is effective as of the Effective Date, by and between the Company and the Executive. Article 1. Term of Employment 1.1 The Company hereby agrees to employ the Executive and the Executive hereby agrees to serve the Company in accordance with the terms and conditions set forth herein, for |
|
| September 27, 2012 |
Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Press Release Exhibit 99.2 Contact: Mary Coleman Savient Pharmaceuticals, Inc. [email protected] (732) 418-9300 Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) BRIDGEWATER, N.J., September 26, 2012 - Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has granted time-based restricted shares, and time-based and performance-based options to purchase shar |
|
| September 27, 2012 |
Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer Press Release Exhibit 99.1 Savient Pharmaceuticals Names John P. Hamill Chief Financial Officer Bridgewater, NJ., - September 24, 2012 - Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of John P. Hamill as Senior Vice President & Chief Financial Officer effective today. Mr. Hamill brings over 25 years of global financial and administrative operational experience to Sav |
|
| September 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 09/04/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| August 14, 2012 |
Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results Savient Logo Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results EAST BRUNSWICK, N. |
|
| August 14, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 08/08/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| August 14, 2012 |
PARTICIPANTS PARTICIPANTS Corporate Participants Philip K. Yachmetz - Senior Vice President and General Counsel Louis Ferrari - President and Chief Executive Officer David G. Gionco - Group Vice President of Finance Kenneth M. Bahrt - Senior Vice President, Chief Medical Officer Richard Crowley - Executive VP-Biopharmaceutical Operations Other Participants Eric Schmidt - Analyst, Cowen and Co. LLC |
|
| August 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 08/07/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| August 7, 2012 |
FORM 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A For Registration of Certain Classes of Securities Pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 13-3033811 (State of Incorporation) (I.R.S. Employer Identification No.) One Tower Center Ea |
|
| August 7, 2012 |
SAVIENT PHARMACEUTICALS, INC. B Y - L A W S(1) ARTICLE I By-Laws of Savient Pharmaceuticals Inc. Exhibit 3.2 SAVIENT PHARMACEUTICALS, INC. B Y - L A W S(1) ARTICLE I OFFICES Section 1. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. Section 2. The corporation may also have offices at such other places both within and without the State of Delaware as the board of directors may from time to time determine |
|
| August 7, 2012 |
Rights Agreement Exhibit 4.1 RIGHTS AGREEMENT between Savient Pharmaceuticals, Inc. and American Stock Transfer & Trust Company, LLC, as Rights Agent Dated August 6, 2012 Table of Contents Page Section 1. Certain Definitions 1 Section 2. Appointment of Rights Agent 7 Section 3. Issuance of Rights 7 Section 4. Form of Rights Certificates 9 Section 5. Countersignature and Registration 10 Section 6. |
|
| August 7, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 5, 2012 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Co |
|
| August 7, 2012 |
Certificate of Designations Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF SAVIENT PHARMACEUTICALS, INC. Savient Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (hereinafter called the “Corporation”), hereby certifies that the following resolution was adopted by the Board of Directors of the Corporatio |
|
| August 7, 2012 |
SAVIENT PHARMACEUTICALS ADOPTS STOCKHOLDER RIGHTS PLAN Press Release Exhibit 99.1 SAVIENT PHARMACEUTICALS ADOPTS STOCKHOLDER RIGHTS PLAN EAST BRUNSWICK, N.J., August 6, 2012 — Savient Pharmaceuticals, Inc. (“Savient” or the “Company”) (Nasdaq: SVNT) today announced that its Board of Directors has adopted a stockholder rights plan (the “Rights Plan”). Pursuant to the Rights Plan and in accordance with Savient’s certificate of incorporation, Savient’s B |
|
| July 26, 2012 |
Form 8-K Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2012 (June 4, 2012) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 |
|
| July 25, 2012 |
8-K 1 rrd351683.htm GIONCO 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 05/29/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or |
|
| July 13, 2012 |
Press Release Exhibit 99.1 Contact: Mary Coleman Kelly Sullivan / Taylor Ingraham Savient Pharmaceuticals, Inc. Joele Frank, Wilkinson Brimmer Katcher [email protected] [email protected] / [email protected] (732) 418-9300 (212) 355-4449 SAVIENT PHARMACEUTICALS ANNOUNCES CEO APPOINTMENT AND REORGANIZATION PLAN TO DRIVE LONG-TERM GROWTH Louis Ferrari to Become President & Chief E |
|
| July 13, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2012 (July 9, 2012) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Inco |
|
| July 13, 2012 |
Amended and Restated Employment Agreement with Louis Ferrari Exhibit 10.1 EXECUTION COPY Confidential treatment has been requested for portions of this document indicated by [***], which portions are filed separately with the Commission. AMENDED AND RESTATED EMPLOYMENT AGREEMENT The Company and Executive entered into an employment agreement dated as of February 7, 2011(the “Original Employment Agr |
|
| July 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 06/29/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| June 8, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 8, 2012 (June 4, 2012) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incor |
|
| June 8, 2012 |
Letter to Ropes & Gray LLP Exhibit 99.1 MORRIS, NICHOLS, ARSHT & TUNNELL LLP 1201 NORTH MARKET STREET P.O. BOX 1347 WILMINGTON, DELAWARE 19899-1347 (302) 658-9200 (302) 658-3989 FAX David J. Teklits 302 351 9292 302 498 6212 Fax [email protected] June 8, 2012 BY EMAIL AND FEDERAL EXPRESS Thad A. Davis, Esquire Ropes & Gray LLP 3 Embarcadero Center San Francisco, CA 94111-4006 Re: Tang Capital Part |
|
| May 30, 2012 |
Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 05/22/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| May 14, 2012 |
Savient Pharmaceuticals Reports First Quarter 2012 Financial Results DC12233.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing Savient Pharmaceuticals Reports First Quarter 2012 Financial Results EAST BRUNSWICK, N.J. - (May 9, 2012 ) - Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2012, which reflects the Company's continuing commercialization of KRYSTEXXA® (pe |
|
| May 14, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 05/09/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| May 14, 2012 |
DC12236.pdf - Converted by SEC Publisher 4.2, created by BCL Technologies Inc., for SEC Filing Savient Pharmaceuticals Q1 2012 Earnings Call May 9, 2012 Corporate Participants Mary Coleman – Senior Director, Investor Relations & Corporate Communications David Y. Norton – Interim Chief Executive Officer Louis Ferrari – Executive Vice President, President North American Commercial Operations Kenneth |
|
| May 9, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 9, 2012 (May 7, 2012) SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorpo |
|
| May 9, 2012 |
Press Release Exhibit 99.2 Savient Pharmaceuticals Completes Financing and Debt Restructuring Transactions Raises $44 Million in Net Proceeds and Extends Maturity on Significant Portion of its Debt EAST BRUNSWICK, New Jersey, May 9, 2012 /PR Newswire/ — Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it has completed the financing and debt restructuring transactions contemplated |
|
| May 9, 2012 |
Press Release Exhibit 99.1 May 8, 2012 Savient Pharmaceuticals Enters Into Definitive Financing and Debt Restructuring Agreements Will Raise $44 Million in Net Proceeds and Extend Maturity on Significant Portion of its Debt Delaware Court Denies Tang Capital Partners’ Request for Injunction Against Transaction EAST BRUNSWICK, N.J., May 8, 2012 /PRNewswire/ — Savient Pharmaceuticals, Inc. (Nasdaq: |
|
| May 9, 2012 |
Pledge and Security Agreement Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT dated as of May 9, 2012 by and among SAVIENT PHARMACEUTICALS, INC., EACH OF THE OTHER GRANTORS PARTY HERETO and U.S. BANK NATIONAL ASSOCIATION, as Collateral Agent TABLE OF CONTENTS PAGE SECTION 1. DEFINITIONS; GRANT OF SECURITY 1 1.1 General Definitions 1 1.2 Definitions; Interpretation 5 SECTION 2. GRANT OF SECURITY 5 2.1 G |
|
| May 9, 2012 |
Indenture, dated as of May 9,2012 EXHIBIT 4.1 SAVIENT PHARMACEUTICALS, INC. and EACH OF THE GUARANTORS NAMED HEREIN and U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 9, 2012 $170,941,000 Senior Secured Discount Notes due 2019 TABLE OF CONTENTS Page I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.01 Definitions 1 1.02 Other Definitions 22 1.03 Incorporation by Reference of |
|
| May 9, 2012 |
EX-4.2 3 d350031dex42.htm FORM OF GLOBAL UNIT Exhibit 4.2 SAVIENT PHARMACEUTICALS, INC. THIS UNIT HAS BEEN ISSUED WITH “ORIGINAL ISSUE DISCOUNT” (WITHIN THE MEANING OF SECTION 1273 OF THE INTERNAL REVENUE CODE OF 1986, AS AMENDED). UPON WRITTEN REQUEST TO THE CHIEF FINANCIAL OFFICER AT ONE TOWER CENTER, 14TH FLOOR, EAST BRUNSWICK, NEW JERSEY 08816, THE COMPANY WILL PROMPTLY MAKE AVAILABLE TO ANY H |
|
| May 9, 2012 |
EXCHANGE AND PURCHASE AGREEMENT Form of Exchange and Purchase Agreement Exhibit 10.1 EXCHANGE AND PURCHASE AGREEMENT (including any other persons or entities exchanging Existing Notes (as defined below) or purchasing New Notes (as defined below) hereunder for whom the undersigned Holder holds contractual and investment authority, the “Holder”) enters into this Exchange and Purchase Agreement (the “Agreement”) with Savient Pharma |
|
| May 9, 2012 |
Warrant Agreement Exhibit 10.3 WARRANT AGREEMENT Dated as of May 9, 2012 between SAVIENT PHARMACEUTICALS, INC. and U.S. BANK NATIONAL ASSOCIATION, as Warrant Agent TABLE OF CONTENTS Page ARTICLE 1 DEFINED TERMS SECTION 1.1. Definitions 1 SECTION 1.2. Other Definitions 4 SECTION 1.3. Terms Generally 5 ARTICLE 2 Warrant Certificates SECTION 2.1. Issuance and Dating 5 SECTION 2.2. Global Warrants 5 S |
|
| May 8, 2012 |
Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 8, 2012 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 05/04/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| May 1, 2012 |
Regulation FD Disclosure - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 1, 2012 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) (Commi |
|
| April 10, 2012 |
Notice and Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 5, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 03/30/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| April 4, 2012 |
Form S-3 Table of Contents As filed with the Securities and Exchange Commission on April 4, 2012 Registration No. |
|
| April 4, 2012 |
Calculation of Ratios of Earnings to Fixed Charges EXHIBIT 12.1 COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (dollars in thousands) Year Ended December 31, 2011 2010 2009 2008 2007 Earnings: Pretax loss from continuing operations (128,815 ) (73,118 ) (92,924 ) (88,258 ) (60,962 ) Add: Fixed charges 16,416 688 338 719 561 Total Earnings (112,399 ) (72,430 ) (92,586 ) (87,539 ) (60,401 ) Fixed |
|
| March 6, 2012 |
Savient Pharmaceuticals, Inc. 2011 INCENTIVE PLAN EX-99.1 5 d308671dex991.htm SAVIENT PHARMACEUTICALS, INC. 2011 INCENTIVE PLANS Exhibit 99.1 Savient Pharmaceuticals, Inc. 2011 INCENTIVE PLAN 1. Purpose The purpose of this 2011 Incentive Plan (the “Plan”) of Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and moti |
|
| March 6, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on March 6, 2012 Registration No. |
|
| March 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): 02/27/2012 Savient Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Commission File Number: 0-15313 DE 13-3033811 (State or other jurisdiction of (IRS Empl |
|
| March 1, 2012 |
- PRESS RELEASE DATED FEBRUARY 27, 2012 begin 644 rrd33657537246.pdf M)5!$1BTQ+C,-"B7BX\3#0HQ(#`@;V)J#0H\/"]4>7!E+U!A9V4O365D:6%" M;WA;,"`P(#8Q,B`W.3)=+U)O=&%T92`Y,"]297-O=7)C97,\/"]0%LP(#`@,3`P,"`Q,#`P72]&:7)S=$-H87(@,2],87-T0VAA M<@,C8@-30@-3$@-3D@-3D@-S(@,C8@ M-30@-3<@,C,@,C,@,S,@-#@@,CD@-#D@-#0@-#0@,S0@-#0@-#(@-#4@-#8@ M-#8@-#8@-#8@,CD@,C,@-#0@-#(@,C,@-#`@,C@@-#4@,C@@-38@-#0@-#0@ M-C@@-#0@-38@-C4@-#8@-3D@-#4@,C8@-3<@-3`@-#D@-3<@-C(@ |
|
| March 1, 2012 |
-----------------------------Savient Pharmaceuticals DRAFT SVNT 4Q11 Script - CLEAN (00441387-18).DOC -Savient Pharmaceuticals Q4 YE 2011 Earnings Call February 27, 2011 Corporate Participants Philip K. Yachmetz - Senior Vice President and General Counsel David Y. Norton - Interim Chief Executive Officer Louis Ferrari - Executive Vice President, President North American Commercial Operations Kenneth M. Bahrt, M.D. - Senior Vice President, Chief Medi |
|
| February 14, 2012 |
SVNTQ / Savient Pharmaceuticals Inc / SAMANA CAPITAL, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.01 Par Value Per Share (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2012 |
SVNTQ / Savient Pharmaceuticals Inc / SECTORAL ASSET MANAGEMENT INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SAVIENT PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 80517Q100 (CUSIP Number) DECEMBER 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 13, 2012 |
SC 13G/A 1 savientpharmaceuticals13ga12.htm SAVIENT PHARMACEUTICALS, INC. - SCH 13G AMENDMENT NO. 12 CUSIP No. 80517Q100 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.12) Savient Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2011 |
|
| February 10, 2012 |
SVNTQ / Savient Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment savi11a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 80517Q100 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* SAVIENT PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 80517Q100 (CUSIP Number) December 31, 2011 (Date of E |
|
| February 10, 2012 |
SVNTQ / Savient Pharmaceuticals Inc / VANGUARD GROUP INC Passive Investment savientpharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:0 )* Name of issuer: Savient Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 80517Q100 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the |
|
| February 3, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2012 SAVIENT PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 0-15313 13-3033811 (State or Other Jurisdiction of Incorporation) ( |
|
| February 3, 2012 |
Exhibit 99.1 SAVIENT PHARMACEUTICALS Executive Appointment Call February 1, 2012 PARTICIPANTS Corporate Participants Philip K. Yachmetz – Secretary, Senior Vice President & General Counsel Stephen O. Jaeger – Non-Executive Chairman David Y. Norton – Interim Chief Executive Officer Louis Ferrari – Senior Vice President-North American Commercial Other Participants Salveen J. Richter – Analyst, Colli |
|
| February 3, 2012 |
Press Release Exhibit 99.2 Contact: Mary Coleman Kelly Sullivan / Jennifer Friedman Savient Pharmaceuticals, Inc. Joele Frank, Wilkinson Brimmer Katcher [email protected] [email protected] / [email protected] (732) 418-9300 (212) 355-4449 SAVIENT PHARMACEUTICALS APPOINTS DAVID Y. NORTON INTERIM CHIEF EXECUTIVE OFFICER Pre-Announces Range of KRYSTEXXA® Net Sales for Fourth Quart |
